<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095587</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-14</org_study_id>
    <nct_id>NCT02095587</nct_id>
  </id_info>
  <brief_title>Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects</brief_title>
  <acronym>IPI-145-14</acronym>
  <official_title>A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to
      subjects with chronic hepatic impairment and in matched healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nonrandomized, open-label, parallel-group, single oral dose study in subjects with
      chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects. Subjects
      will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and
      normal hepatic function. An optional severe hepatic impairment group will enroll based on
      data from the mild and moderate hepatic impairment groups in comparison to matched healthy
      group. All subjects will receive a single oral dose of IPI-145 25 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of IPI-145 and its primary metabolite, IPI-656</measure>
    <time_frame>Open 72 hours</time_frame>
    <description>PK parameters (AUC, Cmax and t1/2) of IPI-145 and its metabolite, IPI-656 Plasma concentrations of IPI-145 and its metabolite, IPI-656</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following administration of IPI-145</measure>
    <time_frame>10 days</time_frame>
    <description>Safety Findings</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional arm based on results from Arms 1, 2, and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>25 mg single oral capsule</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of nonchildbearing potential between 18-70 years of age

          -  Body Mass Index (BMI): 18.0 - 38.0 kg/m2.

          -  Healthy subjects: in good health, determined by no clinically significant findings
             from clinical evaluations

          -  Hepatic impairment subjects: confirmed hepatic impairment &gt;1 year with etiology of
             chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis,
             autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage
             diseases, or galactosemia

          -  Provided written informed consent prior to any study specific procedures

        Exclusion Criteria:

          -  Women of childbearing potential

          -  Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function,
             acute hepatitis, variceal bleeding within 8 weeks of screening, a history of
             pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy &gt; Grade
             1, current unstable hematologic condition, and/or creatinine clearance &lt; 60 mL/min

          -  Healthy subjects: positive screening test for hepatitis B surface antigen, or
             hepatitis C antibody

          -  ECG at screening or Day -1 showing QTcF â‰¥ 450 msec for healthy subjects or &gt; 500 msec
             for hepatically impaired subjects

          -  Evidence of clinically significant medical conditions

          -  History of gastrointestinal disease or surgery that may affect drug absorption

          -  Positive or indeterminate QuantiFERON-TB Gold test at screening

          -  Any active infection at the time of screening or admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Kenneth Lasseter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

